$22.040
-1.968 (-8.93%)Al cierre
Noticias de ZLAB
Eventos de ZLAB
Zai Lab Reports Small Cell Lung Cancer Trial Data
Zai Lab shared the first data from a global Phase 1b clinical trial evaluating zocilurtatug pelitecan in combination with atezolizumab with and without carboplatin as first-line treatment for extensive-stage small cell lung cancer. The data will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. At the recommended Phase 3 dose of 1.6 mg/kg, zoci plus atezolizumab achieved a confirmed objective response rate of 81.8% and an estimated 6-month progression-free survival rate of 81.9% in 1L ES-SCLC. Among patients with at least six-months follow-up treated at 1.6 mg/kg zoci plus atezolizumab, median progression-free survival and median duration of response were not yet reached after a median follow-up of 10 months. Zoci plus atezolizumab therapy was well-tolerated; Grade greater than3 AEs related to zoci occurred in 9.1% of patients treated at 1.6mg/kg. Global, randomized Phase 3 study in 1L ES-SCLC expected to initiate by year-end 2026. "Despite advances in treatment, extensive-stage small-cell lung cancer remains a devastating disease, with many patients experiencing disease progression within approximately five months of initiating standard first-line treatment," said Rafael Amado, M.D., President, Head of Global Research and Development at Zai Lab. "The high confirmed response rate, encouraging durability, and well-tolerated safety profile we are seeing with a standard chemotherapy-free regimen are particularly compelling. We believe zoci's combination of efficacy and safety positions it to become an ADC backbone of choice in small-cell lung cancer, including in combination with immunotherapies. We are preparing to initiate a global Phase 3 trial of zoci and an Immuno-Oncology regimen and continue to evaluate the potential of combinations with T-cell engagers and IO."
Zai Lab Signs Agreement to Sell 11.34 Million ADS for Approximately $250 Million
Zai Lab Limited announced that it has entered into a securities purchase agreement for the sale of 11,340,000 American Depositary Shares, each representing ten ordinary shares of the Company, to certain investors in a private investment in public equity financing. The purchase price of each ADS is $22.04. Gross proceeds from the PIPE financing are expected to be approximately $250 million, before deducting placement agent fees and other offering expenses. The PIPE financing is expected to close on or about October 27, 2026, subject to customary closing conditions. Zai Lab intends to use the net proceeds from the PIPE financing primarily to support the continued global development of zocilurtatug pelitecan (zoci), the Company's Delta-like ligand 3 -targeting antibody-drug conjugate. Leerink Partners is acting as exclusive placement agent for the PIPE financing. Ropes & Gray is acting as legal advisor to Zai Lab.
Zai Lab Partners with argenx for Strategic Collaboration
Zai Lab (ZLAB) and argenx…
Zai Lab Reports Q2 Revenue of $106.3M
Reports Q2 revenue $106.3M, consensus $103.8M. "Zai Lab is entering an exciting new chapter in our evolution," said CEO Samantha Du. "Today, our innovation pipeline is rapidly maturing. We advanced zocilurtatug pelitecan, our potential best-in-class DLL3 antibody-drug conjugate, from Investigational New Drug to global Phase 3 in under two years, and our growing portfolio of internally developed medicines, including ZL-1503, gives us confidence that innovation will increasingly drive Zai Lab's next phase of growth. Meanwhile, we continue to strengthen our commercial business. This quarter, we sharpened our commercial focus, delivered sequential revenue growth, maintained commercial profitability, and laid the foundation for a return to meaningful growth in 2027. Together, these achievements position Zai Lab to create long-term value for patients and shareholders."
Zai Lab Receives FDA Orphan Drug Designation
Zai Lab announced the U.S. Food and Drug Administration has granted Orphan Drug Designation to zocilurtatug pelitecan, the Company's potential first-in-class Delta-like ligand 3 antibody-drug conjugate, for the treatment of neuroendocrine carcinomas. NECs are aggressive malignancies that frequently express DLL3. There are no available targeted therapies and no approved standard of care for NECs in previously treated patients. The U.S. FDA previously granted Fast Track designation to zoci for extrapulmonary NECs, as well as FTD and ODD to zoci for small cell lung cancer, the most significant pulmonary NEC and one of the most aggressive and lethal solid tumors. The European Medicines Agency has also granted ODD to zoci for pulmonary NECs.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.